Study of idiotopic suppression induced by anti-cross-reactive idiotype monoclonal antibody in the anti-p-azophenylarsonate antibody response. 1986

J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain

A/J mice immunized with p-azophenylarsonate coupled to keyhole limpet hemocyanin produce antibodies expressing a cross-reactive idiotype (CRIA). The pretreatment of A/J mice with anti-idiotypic polyclonal or monoclonal antibody directed against the major cross-reactive idiotype (CRIA) borne by p-azophenylarsonate-specific antibody can lead to idiotypic suppression. In this study, we investigate this idiotypic suppression by using four mAb2 (E4, H8, E3, 2D3) recognizing distinct idiotopes whose expression is related to the presence of particular gene segments of the heavy chain V region. 2D3 expression has been related to the presence of some amino acid in the CDR2 region of the VH gene segment derived from the germ line VH IdCR11. So far, the latter is the only germ-line gene coding for CRIA+ antibody that has been identified in the A/J genome. E4 and H8 expression has been related to the use of a particular D segment, whereas E3 expression has been attributed to certain combinations of D and JH segments. Therefore, we might expect independent regulation of the expression of those various idiotopes in relation to the mechanism of gene recombination. Indeed, we observed that 2D3-suppressed A/J mice still produce the three other idiotopes, suggesting the recombination of those particular D and J segments with a different VH gene. Such a gene has been identified in the genome of BALB/c mice. A/J mice pretreated with one of the other three mAb2 are generally cosuppressed for the expression of E4, H8, and E3, but they still produce 2D3+ antibody. In this case, the IdCR11 VH germ-line gene is most probably recombined with different D and J segments. Molecular evidence for the existence of such molecules has also been presented in the literature. So our serologic data on idiotopic suppression in the arsonate system can be compared with recent data provided by molecular genetics.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007130 Immunoglobulin Idiotypes Unique genetically-controlled determinants present on ANTIBODIES whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the IMMUNOGLOBULIN VARIABLE REGION of both immunoglobin polypeptide chains. Idiotypes, Immunoglobulin,Ig Idiotypes,Idiotype, Ig,Idiotype, Immunoglobulin,Idiotypes, Ig,Ig Idiotype,Immunoglobulin Idiotype
D010132 p-Azobenzenearsonate A hapten capable of eliciting both antibody formation and delayed hypersensitivity when bound to aromatic amino acids, polypeptides or proteins. It is used as an immunologic research tool. Azophenylarsonate,para-Azobenzenearsonate,p Azobenzenearsonate,para Azobenzenearsonate
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D005260 Female Females
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
July 1986, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
September 1976, Immunochemistry,
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
July 1986, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
April 1981, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
July 1983, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
January 1981, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
June 1980, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
October 1990, Journal of immunology (Baltimore, Md. : 1950),
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
January 1977, Cold Spring Harbor symposia on quantitative biology,
J R Hiernaux, and J Marvel, and P Meyers, and M Moser, and O Leo, and M Slaoui, and J Urbain
April 1983, The Journal of experimental medicine,
Copied contents to your clipboard!